Oculoplastics News

Horizon Therapeutics has received a prior approval supplement for its previously approved biologics license application so that it can manufacture more Tepezza for the treatment of thyroid eye disease, according to a press release.

Survey data show that the symptom burden of thyroid eye disease persists during the chronic phase of the disease, with most patients reporting continued low quality of life even after systemic glucocorticoid therapy or surgery.

Some currently marketed orbital implants were cleared through equivalence to a later-recalled device, according to a poster at the virtual American Society of Ophthalmic Plastic and Reconstructive Surgery annual meeting.

Michigan laws reduced opioid prescribing patterns following oculoplastic and orbital procedures, according to a cross-sectional study.

For the most part, cosmetic surgeons treat patients with reasonable goals who want to look better, refreshed or rejuvenated.

Additional data from the OPTIC-X extension trial and pooled analysis of phase 2 and 3 trial data confirm the efficacy of teprotumumab for the treatment of thyroid eye disease in the longer term and at different degrees of disease severity.

Adults with active thyroid eye disease assigned the human monoclonal antibody teprotumumab experienced improvements in disease outcomes that persisted nearly 1 year after receiving the last trial dose, new study data show.

What abnormalities of the lower eyelid do you see after blepharoplasty? What causes them and how are they avoided? How do I know if a tarsal trip procedure will be helpful? How long do you wait before considering surgical intervention?

Two of five people with Graves’ disease worldwide have thyroid eye disease, with higher rates among Asian populations vs. other ethnicities, according to a meta-analysis published in Clinical Endocrinology.

Blepharitis, or eyelid margin disease, is a common condition that affects all ages, ethnicities and genders.